| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.073 | 0.6 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.041 | 0.6 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |